
The Food and Drug Administration has created the first shortcut to the U.S. market for “biosimilar” medicines - cheaper versions of expensive and complex biologic drugs such as infliximab for rheumatoid arthritis, etanercept for plaque psoriasis and psoriatic arthritis, and erythropoietin for anemia.
